Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 1.00 |
| ▸ | PSMA7 | O14818 | 2/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 2/20 | 1.00 |
| ▸ | PSMA1 | P25786 | 2/20 | 1.00 |
| ▸ | PSMA2 | P25787 | 2/20 | 1.00 |
| ▸ | PSMA3 | P25788 | 2/20 | 1.00 |
| ▸ | PSMA4 | P25789 | 2/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 2/20 | 1.00 |
| ▸ | PSMB9 | P28065 | 2/20 | 1.00 |
| ▸ | PSMA5 | P28066 | 2/20 | 1.00 |
| ▸ | PSMB4 | P28070 | 2/20 | 1.00 |
| ▸ | PSMB6 | P28072 | 2/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 2/20 | 1.00 |
| ▸ | PSMB10 | P40306 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Z)-Piplartine SCHEMBL30013548 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| Piplartine SCHEMBL2465593 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL12675623 | 0.93 | ALDH1A1 (0.87) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL15422557 | 0.93 | ALDH1A1 (0.87) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL15422559 | 0.93 | ALDH1A1 (0.87) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL173090 | 0.91 | ALDH1A1 (0.83) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL25283508 | 0.90 | ALDH1A1 (0.82) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL173088 | 0.90 | ALDH1A1 (0.82) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL25283503 | 0.89 | ALDH1A1 (0.80) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL25243729 | 0.89 | ALDH1A1 (0.80) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1005 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | claimed |
| US-20250387443-A1 | ENHANCING ONCOLYTIC VIROTHERAPY WITH A COMBINATION OF NUCLEAR EXPORT INHIBITOR AND MYXOMA VIRUS ACTIVATING CELL DEATH PATHWAYS | UNIV ARIZONA STATE (US) | 2025-12-25 | — | — | US | claimed |
| EP-4651865-A2 | COMBINATION THERAPY FOR CANCER USING ROS-ACTIVATED PRODRUGS AND ROS-AMPLIFYING THERAPEUTICS | UWM Research Foundation, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| WO-2025229029-A1 | CONJUGATE OF A SENOTHERAPEUTIC MOIETY AND A LIPID-TARGETING MOIETY | GORGOULIS VASSILIS G (GR) | 2025-11-06 | — | — | WO | claimed |
| US-20250295668-A1 | METHODS FOR INDUCING COLANIC ACID BIOSYNTHESIS | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-09-25 | — | — | US | claimed |
| EP-4365590-B1 | AGENT TARGETING DOUBLE-MEMBRANE ORGANELLE DNA | JUNTENDO EDUCATIONAL FOUND (JP) | 2025-09-24 | — | — | EP | claimed |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-09-18 | — | — | US | claimed |
| EP-4598515-A1 | PHYTOCHEMICAL FORMULATIONS FOR TREATING STRESS AND ANXIETY | GBS Global Biopharma, Inc. (CA) | 2025-08-13 | — | — | EP | claimed |
| US-20250248926-A1 | AN INJECTABLE MICROPARTICLE SYSTEM AND METHOD OF PREPARING THEREOF | AMRITA VISHWA VIDYAPEETHAM (IN) | 2025-08-07 | — | — | US | claimed |
| US-20250249056-A1 | CANCER THERAPIES COMPRISING A NUCLEAR EXPORT INHIBITOR AND AN ONCOLYTIC VIRUS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-08-07 | — | — | US | claimed |
| EP-3955884-A1 | A PERSONAL CARE COMPOSITION COMPRISING PIPERLONGUMINE AND PROCESS FOR PRODUCING THE COMPOSITION | UNILEVER GLOBAL IP LIMITED (GB) | 2022-02-23 | — | — | EP | claimed |
| CN-114073693-A | Application of piperlongumine in inhibiting activation of NLRP3 inflammatory corpuscle | 华南理工大学 | 2022-02-22 | — | — | CN | claimed |
| CN-112266352-B | Piperlongumine derivative and preparation method and application thereof | 绍兴文理学院 | 2022-02-08 | — | — | CN | claimed |
| CN-114025772-A | Compositions and methods for treating RAS mutant cancers | 纪念斯隆凯特琳癌症中心 | 2022-02-08 | — | — | CN | claimed |
| CN-113980897-A | Dental pulp stem cell culture medium and culture method | 李保建 | 2022-01-28 | — | — | CN | claimed |
| CN-113975275-A | New use of piperlongumine for inhibiting programmed necrosis | 宜昌市第一人民医院（三峡大学人民医院） | 2022-01-28 | — | — | CN | claimed |
| WO-2022016267-A1 | SENOTHERAPEUTIC DRUGS FOR AGE-RELATED DISEASES AND CANCER | HAGLUND LISBET AGNETA (CA) | 2022-01-27 | — | — | WO | claimed |
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | claimed |
| US-8968755-B2 | Topical base and active agent-containing compositions, and methods for improving and treating skin | SCHLESSINGER JOEL (US) | 2015-03-03 | — | — | US | claimed |
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | SCHLESSINGER JOEL (US) | 2013-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | GLUL, GGT1, GLS | ALDH1A1 438/4885TP53 2899/4885HSD17B10 1389/4885 |
| US-20250387443-A1 | ENHANCING ONCOLYTIC VIROTHERAPY WITH A COMBINATION OF NUCLEAR EXPORT INHIBITOR AND MYXOMA VIRUS ACTIVATING CELL DEATH PATHWAYS | IL15RA, IL15, NXF1 | ALDH1A1 4378/4885TP53 75/4885HSD17B10 4409/4885 |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | ALDH1A1 916/4885TP53 3896/4885HSD17B10 2935/4885 |
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | FANCI, FANCF, FANCD2 | ALDH1A1 3934/4885TP53 1995/4885HSD17B10 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.